glp 1 agonist drugs side effects long term of agonists glp-1 TrimRX GLP-1 receptor agonists and next-generation – Managing Side Effects of GLP-1

( Erratum in: Int J Clin Pract

It is well-established based on evidence accrued during the last three decades that high plasma concentrations of cholesterol-rich atherogenic lipoproteins are causatively linked to CVD, and that lowering these reduces atherosclerotic cardiovascular events in humans ( APOC3 - the gene for apolipoprotein (apo) C-III - has emerged as being particularly important as a regulator of triglyceride transport and a novel therapeutic target to reduce dyslipidaemia and CVD risk ( Structure and Regulation of APOC-III APOC3 is expressed in hepatocytes and, to a lesser extent in enterocytes ( 0 , monosialylated apoC-III 1 and disialylated apoC-III 2 ( The transcription rate of APOC3 is decreased by insulin (Figure 1) ( APOC3 via hepatic nuclear factor-4 ( HNF4) and carbohydrate-responsive element binding protein (ChREBP) ( APOC3 expression is therefore upregulated in states of insulin resistance (characterized by insulin resistance and hyperglycemia), and recent results demonstrate that glycaemic control is a major determinant of apoC-III secretion rate in vivo (as measured by stable isotope technology) and thus plasma apoC-III levels ( Figure 1 APOC3 antisense oligonucleotides (ASO) reduces hepatic APOC3 expression ( The regulation of hepatic apoC-III expression is now reasonably well-understood, but much less is known of the control of apoC-III synthesis and secretion in the intestine

Semaglutide: should the media slim down its enthusiasm

Womens Health Reports